GlassScriptPhysician profile
James J Hwang
NPI 1659803146
$1,823.36
in general payments reported to CMS, 2019-2025
15 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $16.09 · 2021: $138 · 2022: $387 · 2023: $651 · 2024: $53.86 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $433.47 | 2021-2025 | Therasphere Administration Set |
| Ovik Health, LLC | $233.07 | 2025 | Assist Silver |
| Corcept Therapeutics | $214.34 | 2023 | Korlym |
| Mallinckrodt Hospital Products INC. | $132.69 | 2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $114.35 | 2019 | |
| Pfizer INC. | $111.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.94 | 2023-2024 | Entyvio |
| Medtronic, INC. | $85.16 | 2023 | Appose Ulc |
| Abbvie INC. | $71.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.39 | 2019 | |
| Novo Nordisk INC | $45.08 | 2019 | |
| Genzyme Corporation | $25.20 | 2023 | |
| Janssen Biotech, INC. | $19.88 | 2023 | Stelara |
| Ardelyx, INC. | $19.18 | 2023 | Ibsrela |
| Ibsa Pharma INC. | $16.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.